Literature DB >> 9766920

Epidemiological data in polycythaemia vera: a study of 842 cases.

Y Najean1, J D Rain, C Billotey.   

Abstract

An epidemiological study of 842 polycythaemic patients (entered between 1980 and 1997 in the French investigational prospective protocols) is presented. The global incidence is approximately 0.8-1.5/100,000/year in the reference area (Ile-de-France and surrounding areas). It increases linearly with age until 80, which suggests that several mutational somatic events are necessary. There was a slight male excess (sex-ratio 1.2, after correction for the percentage of male and female French people still living at risk). We did observe a slight excess of PV in the population of Jewish ancestry. A surprising excess of former blood donors (20.7% of the PV cases, compared to 8% estimated in the reference population) was observed. Only a few cases of familial myeloproliferative diseases and occurence of leukemia in the family of our patients have been observed; even if slight, this excess is statistically significant. In contrast, no excess of carcinomas was observed either in the family or in the patients' antecedents. We did not find any excess of radiation exposure in our cases. When analysing the previous occupation of our patients a possible excess of physicians and of patients previously working in occupations using solvents and glues was found, but this finding needs confirmation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766920

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  11 in total

1.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

2.  Central retinal artery occlusion as a presenting manifestation of polycythaemia vera.

Authors:  Karthik Rao; Shailaja Bhat Shenoy; Yogish Kamath; Smita Kapoor
Journal:  BMJ Case Rep       Date:  2016-10-20

3.  Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Authors:  Alexis D Leal; Carrie A Thompson; Alice H Wang; Robert A Vierkant; Thomas M Habermann; Julie A Ross; Ruben A Mesa; Beth A Virnig; James R Cerhan
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

Review 4.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 5.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

Review 6.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

7.  Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis.

Authors:  Serena Pelusi; Federica Iuculano; Rosa Lombardi; Paolo Francione; Umberto Gianelli; Anna Ludovica Fracanzani; Silvia Fargion
Journal:  Intern Emerg Med       Date:  2018-09-14       Impact factor: 3.397

8.  Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben Mesa; Xiaomei Ma
Journal:  Int J Cancer       Date:  2020-01-29       Impact factor: 7.396

9.  Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

Authors:  Nikolai A Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N Hofmann; Linda M Liao; Amer M Zeidan; Ruben A Mesa; Xiaomei Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-31       Impact factor: 4.254

Review 10.  Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN.

Authors:  Gajalakshmi Ramanathan; Brianna M Hoover; Angela G Fleischman
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.